The abstract is read at the publisher; the summary is JClub's.
ExPEC9V failed to prevent first invasive Escherichia coli disease from ExPEC9V O-serotypes in adults aged 60+ (14·63% VE; 95% CI -106·57 to 65·38).
- Why it matters: Invasive Escherichia coli disease can cause bacteraemia and sepsis, and there is a need for effective prevention in older adults at higher risk.
- What they did: In a phase 3, randomised, double-blind, placebo-controlled trial across 332 sites in 20 countries, 8858 received ExPEC9V and 8843 placebo; the primary endpoint was first IED from ExPEC9V O-serotypes in the per-protocol set.
- The result: Among 17,637 per-protocol participants, 24 IED cases occurred (11 vaccine, 13 placebo), with an acceptable safety profile but no protective efficacy, despite robust and sustained antibody responses; development was discontinued.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.